<div id="readability-page-1"><p>Alumis (NASDAQ:ALMS - Get Free Report) will likely be announcing its  Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $2.4930 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.</p><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%.  On average, analysts expect Alumis to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year. </p><h2>Alumis Price Performance</h2><p>Shares of NASDAQ:ALMS opened at $26.13 on Wednesday. The firm has a 50 day simple moving average of $25.22 and a 200 day simple moving average of $17.98. The company has a market cap of $3.32 billion, a price-to-earnings ratio of -8.54 and a beta of -0.31. Alumis has a one year low of $2.76 and a one year high of $30.60. </p><h2>Analysts Set New Price Targets</h2><p>ALMS has been the subject of several analyst reports. Morgan Stanley raised their price target on shares of Alumis from $33.00 to $38.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, March 20th. UBS Group  reaffirmed an &#34;outperform&#34; rating on shares of Alumis in a research note on Tuesday, January 6th. Leerink Partners raised their price target on shares of Alumis from $20.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, January 6th. Oppenheimer raised their price target on shares of Alumis from $50.00 to $55.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, March 30th. Finally, Guggenheim raised their price target on shares of Alumis from $18.00 to $32.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, January 7th. One equities research analyst  has rated the stock with a Strong Buy rating, ten have issued  a Buy rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, Alumis presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $38.60.</p><p><b>View Our Latest Analysis on ALMS</b></p><h2>Institutional Investors Weigh In On Alumis</h2><p>Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of  Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock worth $26,000 after buying an additional 4,894 shares during the period.  New York State Common Retirement Fund increased its position in shares of  Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock worth $35,000 after buying an additional 7,467 shares during the period.  BNP Paribas Financial Markets increased its position in shares of  Alumis by 104.9% during the third quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company's stock worth $47,000 after buying an additional 6,027 shares during the period.  The Manufacturers Life Insurance Company acquired a new stake in  Alumis in the second quarter worth $56,000.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in  Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after purchasing an additional 4,926 shares during the period. </p><h2>About Alumis</h2> (Get Free Report)<p>Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words &#34;allumer&#34;-French for illuminate-and &#34;immunis&#34;-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.</p><h2>Read More</h2><ul><li>Five stocks we like better than Alumis</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxNUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxNUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alumis Right Now?</h2><p>Before you consider Alumis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.</p><p>While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALMS

<p>Alumis (NASDAQ:ALMS) is set to release its Q1 2026 earnings on May 13, with analysts predicting a loss of $0.79 per share and revenue of $2.493 million. The company previously reported a loss of $0.95 per share for Q4 2025, missing estimates. Alumis shares opened at $26.13, with a market cap of $3.32 billion. Analysts have raised price targets for the stock, with an average target of $38.60. Institutional investors have also increased their holdings in the company recently.</p>

Market Beat

Alumis

Morgan Stanley

UBS Group AG

Oppenheimer

BNP Paribas

Manulife Financial

MANULIFE-S

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Alumis (ALMS) to Release Quarterly Earnings on Wednesday